AlphAIAlphAI — Financial news for AI agents
investing.com$ZTS

Zoetis stock rises 2% on beating earnings and revenue estimates

Zoetis Inc. (ZTS) reported Q3 earnings of $1.75 per share, beating estimates by $0.24, and revenue of $2.4B, up from $2.3B expected but down 1% YoY. Shares rose 2.09% premarket. The company raised its full-year adjusted EPS guidance to $6.25-$6.35, with revenue guidance narrowed to $9.22B-$9.32B. U.S. segment revenue fell 6%, while international revenue grew 4%.

Original reporting
investing.com
Published Nov 5, 2026, 12:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ZTS
Bullish
high confidence
Mentioned
$ZTS
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ZTSBullishHigh
01

Why it matters

The earnings beat and guidance raise expectations for continued growth, especially in livestock and diagnostics, while companion‑animal pricing remains a headwind.

02

Market read

The surprise earnings and guidance lift Zoetis stock and may influence the broader health‑care sector.

03

What to watch

Potential pressure from companion‑animal pricing sensitivity may limit upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Zoetis is the leading animal health company, and its earnings are closely watched for trends in companion‑animal and livestock segments.

Company-level read

Ticker impact

$ZTSBullishHigh confidence
Context

Zoetis reported Q3 earnings that beat estimates and raised full-year EPS guidance, causing a 2% pre‑market price rise.

Expected impact

upward pressure as investors price in the earnings beat and higher guidance

Evidence & confidence

The beat was $0.24 above consensus and guidance was raised, which historically drives short‑term buying.

Market effects

Sector

Animal health sector may see broader rally on Zoetis strength.

Regional

U.S. market sentiment boosted by a large‑cap earnings beat.

Global

Limited to investors tracking health‑care and biotech equities.

Counterpoint

What could challenge this read

If guidance misses consensus on revenue, the rally could be short‑lived.

Key entities

  • company
    Zoetis Inc.

    Animal health company reporting Q3 results.

Read at source← All news

StoryZoetis reports Q3 2026 results, beats EPS and raises full‑year guidance

Also covered by

5 outlets

Related articles

$ZTSMedAI 8/10

Zoetis (ZTS) Q3 2026 Earnings Call Transcript

Zoetis (ZTS) reported Q3 2026 earnings with revenue and adjusted net income declining as expected. The company cited challenges in pet care due to rising costs and changing pet ownership trends, while livestock demand remains strong. Zoetis narrowed its full-year revenue guidance to the high end of its range and highlighted investments in key franchises and innovation.

finance.yahoo.com
$ZTSMedAI 8/10

Zoetis 3Q 2026: Revenue $2.39B, EPS $1.44 — 10-Q Summary

Zoetis reported 3Q 2026 revenue of $2.39B, down 1% YoY, and net income of $1.44B, down 18%. Declines were driven by softer U.S. companion-animal demand, competition, and lower prices, partially offset by livestock growth and favorable exchange rates. Higher restructuring costs also impacted earnings. U.S. companion-animal revenue fell 8%, while U.S. livestock and international revenues rose 5% and 4%, respectively.

tradingview.com
$ZTSHighAI 8/10

Why is Zoetis stock climbing today?

Zoetis (ZTS) stock rose 2.4% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.75 vs. $1.51 and revenue of $2.4B vs. $2.3B. The company raised full-year EPS guidance to $6.25–$6.35. International sales grew 4%, while U.S. companion animal business faced challenges. The stock traded near $91.30 premarket, below its 52-week high of $132.49.

investing.com